Zinger Key Points
- REGENXBIO doses first patient in its trial for Duchenne gene therapy.
- The company announces positive data from Phase I/II part of AFFINITY DUCHENNE trial.
- Get New Picks of the Market's Top Stocks
REGENXBIO Inc. RGNX stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
The Details: The company announced that it has dosed the first patient in its trial for RGX-202, a potential gene therapy designed to treat Duchenne muscular dystrophy.
In addition, REGENXBIO announced positive results from the Phase I/II portion of the study. Specifically, the company saw functional improvements in all patients treated with dose level one and dose level two at 12 and 9 months respectively. A favorable safety profile was observed at both dose levels, with no serious adverse events.
“The totality of our data demonstrates that RGX-202 provides evidence of improving outcomes for boys with Duchenne and altering the trajectory of this devastating disease, with consistent, robust expression of our novel microdystrophin translating into significant clinical benefit,” said Curran M. Simpson, President and CEO of REGENXBIO
“Based on the strength of the Phase I/II data and our positive discussions and alignment with the FDA, we are quickly advancing RGX-202 toward a BLA filing in 2026 using the accelerated approval pathway. We continue to evaluate opportunities to expand the RGX-202 program to benefit Duchenne patients worldwide.”
How To Buy REGENXBIO Shares
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Regenxbio's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
RGNX Price Action: At the time of writing, REGENXBIO stock is trading 7.7% higher at $10.37, according to data from Benzinga Pro.
Image: Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
